Dermatitis Atopic Clinical Trial
Official title:
A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: - To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching) - To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting - To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD - To collect safety data on study participants
Participants enrolled in the study will be followed for 5 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06015308 -
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
|
Phase 2 | |
| Completed |
NCT04135560 -
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT06130566 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT06192563 -
A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
|
||
| Completed |
NCT05624112 -
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
|
Phase 4 | |
| Recruiting |
NCT06224348 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
|
Phase 3 | |
| Completed |
NCT05214326 -
A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
|
||
| Recruiting |
NCT06241118 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05983068 -
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT04718870 -
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT05235724 -
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
|
||
| Recruiting |
NCT06181435 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
|
Phase 3 | |
| Recruiting |
NCT05492578 -
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
|
Phase 2 | |
| Recruiting |
NCT03687359 -
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
|
||
| Active, not recruiting |
NCT03849716 -
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
|
||
| Recruiting |
NCT05769777 -
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04823130 -
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
|
Phase 4 |